We've updated Patient-Clinician Communication guidelines. New recommendations cover:
💬 Core communication skills
🔎 Prognosis & treatment selection
🫶 End-of-life care
🥼 Clinician training

Improving the dialogue for better cancer care. Read the update: https://bit.ly/3NnMnMR

Do you have an impactful research idea?
One that could improve care or advance science?

Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 .

🔗https://ow.ly/Gicm50YqcbZ

#Oncology #ESMOYOC

Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors - OncoDaily Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors / Aurélien Marabelle, cancer, fight against cancer, Global fight against cancer, Nieves

PEM in MSI and dMMR advanced solid tumors - Nieves Martinez Lago
@dramartinezlago.bsky.social

oncodaily.com/science/2541...

#Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily

📢 FDA grants accelerated approval to encorafenib + cetuximab + mFOLFOX6 for treatment-naïve mCRC with BRAF V600E mutation. BREAKWATER trial shows 61% ORR!
Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue.
@oncoalert.bsky.social @fda.gov
@oncbrothers.bsky.social

🔑 concepts in #NETs surgery

Mesenteric nodal disease classification👉🏻4 levels
4⃣ - unresectable
1⃣2⃣3⃣ - need tailored mesentery resection to spare bowel
✅Resectable if can salvage >=2 proximal SMA branches

📝 tinyurl.com/2w952fjv

#NETSky #HPBSky #SurgSky #OncSky

Where should we place cabozantinib in the treatment algorithm of patients with NETs. Excellent review by Dr. Bhavana Konda from Ohio State University.

#NANETS24 #NETsSky

Is PRRT safe in patients with NETs and extensive bone metastases…? Excellent presentation by Dr. Osama Mosalem at Mayo Florida @nanets.bsky.social 2024. Higher G3/G4 heme tox (29%), some persistent heme tox but no signal of increase in treatment related myeloid neoplasia. #NANETS24 #NETsSky #OncSky

Next big things in #NETs care @cives_mauro at #NANETS24
▪️new PRRT regimens: alpha-emiting RLT
▫️BiTEs for NEC
▪️❓CAR T cell therapy
▫️tumor vaccines 💉
@nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky

PD-L1 thresholds predict efficacy of ICI in 1L treatment of advanced GEA. A systematic review and meta-analysis of 7 phase III randomized trials
👉Optimal CPS cut-off is uncertain.
👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI.

doi.org/10.1016/j.es...

El próximo 29 y 30 de noviembre tendrá lugar la XII Reunión del Grupo Gallego de investigación en Tumores Digestivos @Grupo_GITUD. Os esperamos en a Sede Afundacion de Ferrol.

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm - Nature Reviews Clinical Oncology Over the past few years, several novel therapies, including targeted therapies for specific subgroups as well as several non-targeted therapies, have been developed and approved for patients with chem...

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
👉 FTD/TPI+BEV, REG and FRU for unselected pts
👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations
👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt
www.nature.com/articles/s41...

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms...

Must read for NET providers - the CommNETs/NANETS statement on NET biomarkers. An extremely useful document, detailing the clinical utility of NET biomarkers after thorough review of the evidence. The short of it is that most are not recommended for routine use.

jamanetwork.com/journals/jam...

<em>Journal of Neuroendocrinology</em> | BSN Journal | Wiley Online Library Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine ne...

You unsure of how to monitor responses in NET patients after PRRT? All these different scans and blood tests confusing? Worry not, this team has you covered...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...

Adjuvant NIVO+IPI in pts with resected GC and GEJ following preoperative CT with high risk for recurrence (ypN+ and/or R1): VESTIGE study, phase 3.
👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99)
👉12mDFS 47.1% vs 64.0%
Give adjuvant FLOT even when there's residual cancer.
doi.org/10.1016/j.an...

Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX after 3 months of FOLFOX in HER2-negative GC/GEJ cancer
@TheLancetOncol
doi.org/10.1016/S1470-…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊

Hi! I’m Dr. Nieves Martínez Lago, a Medical Oncologist focused on GI, NET and endocrine tumors. I’m passionate about sharing knowledge and connecting with other professionals. Looking forward to engaging in insightful discussions and expanding my network. Feel free to reach out! #medsky #oncsky

Neuroendocrine differentiation and serotonin expression in oesophageal adenocarcinomas after neoadjuvant therapy: correlation with clinicopathological features and outcome Expression of neuroendocrine markers in oesophageal adenocarcinoma after neoadjuvant chemoradiation is independently associated with reduced overall survival. Assessment of neuroendocrine differentia....

Here is a common problem in GI oncology, neuroendocrine differentiation (NED) in non-neuroendocrine carcinoma. According to many studies, outcomes are worse if NED is present (colorectum, esophagus, stomach, lung...). I get asked this often... #NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...